CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS
Oral fingolimod has been recently accepted as a treatment for relapsing Multiple Sclerosis (MS) by the Indonesian Food and Drug Administration. The number of MS patients is increasing in Indonesia. There is a critical need of systematically reviewing the new medication for both efficacy and safety....
Main Authors: | Rizaldy Taslim Pinzon, Rosa De Lima Renita Sanyasi |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Sanata Dharma
2017-11-01
|
Series: | Jurnal Farmasi Sains dan Komunitas |
Subjects: | |
Online Access: | http://e-journal.usd.ac.id/index.php/JFSK/article/view/606 |
Similar Items
-
Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01) -
A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
by: Mehrdokht Mazdeh, et al.
Published: (2019-04-01) -
Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xin Wu, et al.
Published: (2021-05-01) -
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
by: Angelo Ghezzi, et al.
Published: (2019-07-01) -
Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01)